Aims The receptor for advanced glycation endproducts, RAGE, is a multiligand receptor and NF-κB activator leading to perpetuation of inflammation. We investigated whether and how RAGE is involved in mediation of anti-inflammatory properties of protein C. Methods and Results We analyzed the effect of protein C on leukocyte adhesion and transmigration in WT- and RAGE-deficient mice using intravital microscopy of cremaster muscle venules during trauma- and TNFα-induced inflammation. Both, protein C (PC, Ceprotin, 100 U/kg) and activated protein C (aPC, 24 μg/kg/h) treatment significantly inhibited leukocyte adhesion in WT mice in these inflammation models. The impaired leukocyte adhesion after trauma-induced inflammation in RAGE knockout mice could not be further reduced by PC and aPC. After TNFα-stimulation, however, aPC but not PC treatment effectively blocked leukocyte adhesion in these mice. Consequently, we asked whether RAGE is involved in PC activation. Since RAGE-deficient mice and endothelial cells showed insufficient PC activation, and since thrombomodulin (TM) and endothelial protein C receptor (EPCR) are reduced on the mRNA and protein level in RAGE deficient endothelial cells, an involvement of RAGE in TM-EPCR-dependent PC activation is likely. Moreover, TNFα-induced activation of MAPK and upregulation of ICAM-1 and VCAM-1 are reduced both in response to aPC treatment and in the absence of RAGE. Thus, there seems to be interplay of the RAGE and the PC pathway in inflammation. Conclusion RAGE controls anti-inflammatory properties and activation of PC, which might involve EPCR and TM.
References
[1]
Jackson CJ, Xue M (2008) Activated protein C–An anticoagulant that does more than stop clots. The International Journal of Biochemistry & Cell Biology 40: 2692–2697. doi: 10.1016/j.biocel.2007.12.013
[2]
Rezaie AR (2010) Regulation of the Protein C Anticoagulant and Antiinflammatory Pathways. Curr Med Chem 17: 2059. doi: 10.2174/092986710791233706
[3]
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis. Journal of Biological Chemistry 276: 11199–11203. doi: 10.1074/jbc.c100017200
[4]
Madhusudhan T, Wang H, Straub BK, Gr？ne E, Zhou Q, et al. (2012) Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 119: 874–883. doi: 10.1182/blood-2011-07-365973
[5]
Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, et al. (2013) Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proceedings of the National Academy of Sciences 110: 648–653. doi: 10.1073/pnas.1218667110
[6]
Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678–689. doi: 10.1038/nri2156
[7]
Frommhold D, Kamphues A, Dannenberg S, Buschmann K, Zablotskaya V, et al. (2011) RAGE and ICAM-1 differentially control leukocyte recruitment during acute inflammation in a stimulus-dependent manner. BMC Immunology 12: 56. doi: 10.1186/1471-2172-12-56
[8]
Frommhold D, Kamphues A, Hepper I, Pruenster M, Luki？ IK, et al. (2010) RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 116: 841–849. doi: 10.1182/blood-2009-09-244293
[9]
Springer TA (1995) Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration. Annual Review of Physiology 57: 827–872. doi: 10.1146/annurev.ph.57.030195.004143
[10]
Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, et al. (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102: 1499–1505. doi: 10.1182/blood-2002-12-3880
[11]
Elphick GF, Sarangi PP, Hyun Y-M, Hollenbaugh JA, Ayala A, et al. (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 113: 4078–4085. doi: 10.1182/blood-2008-09-180968
[12]
Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, et al. (2007) Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13: 1349–1358. doi: 10.1038/nm1667
[13]
Messaris E BA, Memos N, Chatzigianni E, Boutsikou M, Economou V, Donta I, Theodossiades G, Konstadoulakis MM, Douzinas EE (2010) Administration of human protein C improves survival in an experimental model of sepsis. Crit Care Med 38: 209–216. doi: 10.1097/ccm.0b013e3181b4a972
[14]
Frommhold D, Tschada J, Braach N, Buschmann K, Doerner A, et al. (2011) Protein C Concentrate Controls Leukocyte Recruitment during Inflammation and Improves Survival during Endotoxemia after Efficient in Vivo Activation. The American Journal of Pathology 179: 2637–2650. doi: 10.1016/j.ajpath.2011.07.023
[15]
Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, et al. (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C. The Journal of Experimental Medicine. 204: 2439–2448. doi: 10.1084/jem.20070404
[16]
Kau J-H, Shih Y-L, Lien T-S, Lee C-C, Huang H-H, et al. (2012) Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats. Journal of Biomedical Science 19: 98. doi: 10.1186/1423-0127-19-98
[17]
Sopel MJ, Rosin NL, Falkenham AG, Bezuhly M, Esmon CT, et al. (2012) Treatment with Activated Protein C (aPC) Is Protective during the Development of Myocardial Fibrosis: An Angiotensin II Infusion Model in Mice. PLoS ONE 7: e45663. doi: 10.1371/journal.pone.0045663
[18]
Moore CC, McKillop IH, Huynh T (2013) MicroRNA expression following activated protein C treatment during septic shock. Journal of Surgical Research 182: 116–126. doi: 10.1016/j.jss.2012.07.063
[19]
Angus DC, van der Poll T (2013) Severe Sepsis and Septic Shock. New England Journal of Medicine 369: 840–851. doi: 10.1056/nejmra1208623
[20]
van Zoelen MAD AA, van der Poll T (2011) RAGE during infectious diseases. Frontiers in Bioscience S3: 1119–1132. doi: 10.2741/215
[21]
Lange-Sperandio B, Sperandio M, Nawroth P, Bierhaus A (2007) RAGE Signaling in Cell Adhesion and Inflammation. Current Pediatric Reviews 3: 1–9. doi: 10.2174/1573396310703010001
[22]
Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. The Journal of Clinical Investigation 113: 1641–1650. doi: 10.1172/jci200418704
[23]
Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, et al. (2011) Septic Shock Is Associated with Receptor for Advanced Glycation End Products Ligation of LPS. The Journal of Immunology 186: 3248–3257. doi: 10.4049/jimmunol.1002253
[24]
Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, et al. (2003) The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins. The Journal of Experimental Medicine 198: 1507–1515. doi: 10.1084/jem.20030800
[25]
Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. The Journal of Clinical Investigation 113: 1641–1650. doi: 10.1172/jci200418704
[26]
Schmidt AM, Yan SD, Yan SF, DM S (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99–111. doi: 10.1016/s0167-4889(00)00087-2
[27]
Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26: 1129–1139. doi: 10.1038/sj.emboj.7601552
[28]
Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52: 2251–2263. doi: 10.1007/s00125-009-1458-9
[29]
Ramsgaard L, Englert JM, Manni ML, Milutinovic PS, Gefter J, et al. (2011) Lack of the Receptor for Advanced Glycation End-Products Attenuates E. coli Pneumonia in Mice. PLoS ONE 6: e20132. doi: 10.1371/journal.pone.0020132
[30]
van Zoelen MAD, Schmidt A-M, Florquin S, Meijers JC, de Beer R, et al. (2009) Receptor for Advanced Glycation End Products Facilitates Host Defense during Escherichia coli–Induced Abdominal Sepsis in Mice. Journal of Infectious Diseases 200: 765–773. doi: 10.1086/604730
[31]
van Zoelen M, Achouiti A, van der Poll T (2011) The role of receptor for advanced glycation endproducts (RAGE) in infection. Critical Care 15: 208. doi: 10.1186/cc9990
[32]
Pusterla T, Nèmeth J, Stein I, Wiechert L, Knigin D, et al. (2013) Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology 58: 363–373. doi: 10.1002/hep.26395
[33]
Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, et al. (2001) Characterization of a Mouse Model for Thrombomodulin Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 1531–1537. doi: 10.1161/hq0901.094496
[34]
Esmon CT, Esmon NL, Le Bonniec BF and Johnson AE (1993) [21] Protein C activation. In: K. G. M. Laszlo Lorand, editor editors. Methods in Enzymology. Academic Press. 359–385.
[35]
Liaw PCY, Ferrell G, Esmon CT (2003) A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. Journal of Thrombosis and Haemostasis 1: 662–670. doi: 10.1046/j.1538-7836.2003.00153.x
[36]
Isermann B, Hendrickson SB, Zogg M, Wing M, Cummiskey M, et al. (2001) Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. The Journal of Clinical Investigation 108: 537–546. doi: 10.1172/jci200113077
[37]
Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97: 1685–1688. doi: 10.1182/blood.v97.6.1685
[38]
Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T (2005) A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 12: 138–142. doi: 10.5551/jat.12.138
[39]
Jung U, Ley K (1997) Regulation of E-Selectin, P-Selectin, and Intercellular Adhesion Molecule 1 Expression in Mouse Cremaster Muscle Vasculature. Microcirculation 4: 311–319. doi: 10.3109/10739689709146794
[40]
Forlow SB, Ley K (2001) Selectin-independent leukocyte rolling and adhesion in mice deficient in E-, P-, and L-selectin and ICAM-1. American Journal of Physiology - Heart and Circulatory Physiology 280: H634–H641.
[41]
Jung U, Bullard DC, Tedder TF, Ley K (1996) Velocity differences between L- and P-selectin-dependent neutrophil rolling in venules of mouse cremaster muscle in vivo. American Journal of Physiology - Heart and Circulatory Physiology 271: H2740–H2747.
[42]
Frommhold D, Ludwig A, Bixel MG, Zarbock A, Babushkina I, et al. (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. The Journal of Experimental Medicine 205: 1435–1446. doi: 10.1084/jem.20070846
[43]
Buschmann K, Koch L, Braach N, Mueller H, Frommhold D, et al. (2012) CXCL1-Triggered Interaction of LFA1 and ICAM1 Control Glucose-Induced Leukocyte Recruitment during Inflammation In Vivo. Mediators of Inflammation 2012: 12. doi: 10.1155/2012/739176
[44]
Esmon C (2003) The protein C pathway. Chest 124: 26S–32S. doi: 10.1378/chest.124.3_suppl.26s
[45]
Rezaie AR (2011) The occupancy of endothelial protein c receptor by its ligand modulates the par-1 dependent signaling specifity of coagulation proteases. IUBMB Life 63: 390–396. doi: 10.1002/iub.447
[46]
Guitton C, Cottereau A, Gérard N, Quillard T, Chauveau A, et al. (2011) Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases. American Journal of Physiology - Cell Physiolog 300: C833–C842. doi: 10.1152/ajpcell.00003.2010
[47]
Owen WG, Esmon CT (1981) Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Journal of Biological Chemistry. 256: 5532–5535.
[48]
Esmon CT, Owen WG (2004) The discovery of thrombomodulin. Journal of Thrombosis and Haemostasis 2: 209–213. doi: 10.1046/j.1538-7933.2003.00537.x
[49]
Riewald M, Petrovan RJ, Donner A, Ruf W (2003) Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. Journal of Endotoxin Research 9: 317–321. doi: 10.1177/09680519030090050801
[50]
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway. Science 296: 1880–1882. doi: 10.1126/science.1071699
[51]
Bae J-S, Yang L, Rezaie AR (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proceedings of the National Academy of Sciences 104: 2867–2872. doi: 10.1073/pnas.0611493104
[52]
Rance JB, Follows GA, Cockerill PN, Bonifer C, Lane DA, et al. (2003) Regulation of the human endothelial cell protein C receptor gene promoter by multiple Sp1 binding sites. Blood 101: 4393–4401. doi: 10.1182/blood-2002-05-1570
[53]
Riehl A, Bauer T, Brors B, Busch H, Mark R, et al. (2010) Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation. BMC Genomics 11: 537. doi: 10.1186/1471-2164-11-537
[54]
Tazawa R, Hirosawa S, Suzuki K, Hirokawa K, Aoki N (1993) Functional Characterization of the 5′-Regulatory Region of the Human Thrombomodulin Gene. Journal of Biochemistry 113: 600–606.
[55]
Feistritzer C, Riewald M (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1–phosphate receptor-1 crossactivation. Blood 105: 3178–3184. doi: 10.1182/blood-2004-10-3985
[56]
Minhas N, Xue M, Fukudome K, Jackson CJ (2010) Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. The FASEB Journal 24: 873–881. doi: 10.1096/fj.09-134445
[57]
Uchiba M, Okajima K, Oike Y, Ito Y, Fukudome K, et al. (2004) Activated Protein C Induces Endothelial Cell Proliferation by Mitogen-Activated Protein Kinase Activation In Vitro and Angiogenesis In Vivo. Circulation Research 95: 34–41. doi: 10.1161/01.res.0000133680.87668.fa
[58]
Abeyama K, Stern DM, Ito Y, Kawahara K-i, Yoshimoto Y, et al. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. The Journal of Clinical Investigation 115: 1267–1274. doi: 10.1172/jci22782
[59]
Luo Y, Li S-J, Yang J, Qiu Y-Z and Chen F-P (2013) HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway. Biochemical and Biophysical Research Communications: in press.
[60]
Bae J-S, Rezaie AR (2011) Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952–3959. doi: 10.1182/blood-2011-06-360701
[61]
Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, et al. (2010) The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. The Journal of Clinical Investigation 120: 1971–1980. doi: 10.1172/jci40380
[62]
Fink K, Busch H-J, Bourgeois N, Schwarz M, Wolf D, et al. (2013) Mac-1 Directly Binds to the Endothelial Protein C-Receptor: A Link between the Protein C Anticoagulant Pathway and Inflammation? PLoS ONE 8: e53103. doi: 10.1371/journal.pone.0053103
